Philippine anti-aging clinics: which peptide claims deserve scrutiny?

TL;DR

• “Anti-aging” is too broad to serve as an outcome; WHO frames healthy ageing around functional ability and wellbeing, which can be named and measured.¹
• Human NAD-related trials show why a higher biomarker is not a finished result: changes in NAD+ did not consistently bring matching gains in cognition or physical function.²
• MOTS-c performance findings came from mice, while the human part of the same paper measured the body’s own MOTS-c response to exercise.³
• In the Philippines, readers can use the Philippine FDA Verification Portal to check establishments, health products, approved clinical trials, and official product information.⁴

For Filipino readers, the new language of longevity can arrive as a sleek menu: cellular energy, recovery, sharper thinking, metabolic renewal. The harder question is not whether the science sounds modern. It is whether the promised result matches what researchers actually measured. A blood marker, a mouse treadmill, and a person’s daily function are three different kinds of evidence.² Keeping them separate makes clinic claims easier to read without hype or reflexive dismissal.

Define the promise before judging it

“Anti-aging” can point to appearance, energy, memory, strength, recovery, or years of life. Those are not one outcome. WHO defines healthy ageing as maintaining the functional ability that supports wellbeing in older age.¹ Its examples include meeting basic needs, making decisions, moving, keeping relationships, and contributing to society.¹

That framework gives a reader a useful first question: what changed, and how was it measured? A clinic statement about “cellular age” may refer to a laboratory value, while a reader may hear a promise about feeling or functioning better. The two should not be silently exchanged. Ask for the named outcome, study population, comparison group, and follow-up. If those details stay vague, the scientific language has not yet become a clear claim.

NAD-plus is named here only as the neutral catalog reference below.

NAD+ biology is not an anti-aging verdict

NAD+ is central to cellular metabolism, which explains why researchers study ways to alter its availability.⁵ That biological role does not make every downstream claim automatic. A randomized crossover study followed 24 healthy adults aged 55 to 79 through nicotinamide riboside and placebo periods.⁵ The precursor increased measured markers of NAD+ metabolism over six weeks.⁵

The same study gives the result its boundary. Most measured cardiovascular and physical-function outcomes did not differ between the study periods.⁶ A biomarker can therefore answer, “Did this part of metabolism move?” without answering, “Did ageing slow?” or “Did daily function improve?” The relevant compound matters too. The cited trial tested an oral precursor, not direct NAD+ or a multi-ingredient clinic service.⁵ Each form needs evidence that matches its own claim.

Cognition needs a cognitive outcome

Memory language can make a metabolic marker feel more meaningful than it is. In a placebo-controlled pilot study, 20 older adults with mild cognitive impairment received nicotinamide riboside or placebo over ten weeks.⁷ Blood NAD+ rose in the nicotinamide riboside group, but cognition did not change during the study.⁷

That is not a contradiction. It means the biological measure and the participant-level outcome told different parts of the story. The study also reported exploratory measures, but those do not replace the prespecified cognitive outcome.⁷ For a clinic claim about focus, memory, or “brain age,” the matching evidence should measure that specific function in people. A pathway explanation, a blood change, or a result from another population cannot quietly stand in for it.

Strength and recovery require their own tests

Physical claims also need direct measurements. A randomized crossover trial in 14 older adults with impaired physical function tested a mixture of NAD+ precursors.⁸ It did not find improvement in measured muscle mitochondrial function or exercise efficiency.⁸ The small study concerned one mixture and one population, so it should stay within those limits.⁸

A separate placebo-controlled study included 32 adults aged 55 to 80 and used a standardized muscle-injury model.⁹ The tested nicotinamide riboside and pterostilbene combination did not improve measured muscle stem-cell recruitment or other recovery measures.⁹ These findings do not settle every NAD-related question. They show why a recovery claim needs a recovery outcome from the matching form and population.⁹ Formulation, comparator, and measurement all belong beside the claim.

IV language adds a product-quality question

An IV claim is not only a question about the active ingredient. It is also a question about sterility, ingredients, preparation, and the finished product. The U.S. FDA warned that food-grade NAD+ is not suitable for sterile drug compounding without appropriate processing because microbial or endotoxin contamination can harm patients.¹⁰

The agency also received reports of severe chills, shaking, vomiting, and fatigue after NAD+ injectable drugs, with some people needing medical care.¹¹ Those reports do not establish how often such events occur, and the communication does not describe a particular Philippine clinic.¹¹ It does show why a study about an oral precursor cannot settle the quality or safety of an IV product.⁵ Filipino readers should keep outcome evidence separate from records for the exact establishment and health product.⁴

MOTS-c headlines cross two different models

MOTS-c is a mitochondrial-encoded peptide studied in metabolism and exercise research.³ In one paper, experimental MOTS-c exposure improved physical performance in young, middle-aged, and old mice.³ The human part did something different: researchers measured naturally occurring MOTS-c in muscle and blood around exercise.³

That distinction is the heart of the scrutiny. The mouse performance result does not establish an externally supplied product’s effect in people.³ A rise in the body’s own peptide during exercise also does not show that adding the peptide recreates exercise.³ The paper offers an animal result, while the human observation answers a narrower question.³ Any human performance or longevity headline should keep those lanes visible.

MOTS-c is named here only as the neutral catalog reference below.³

Regulation and product quality answer different questions

The Philippine FDA says its Verification Portal lets the public check licensed establishments, registered or notified health products, approved clinical trials, and selected product information.⁴ A portal entry is specific to what is listed; it should not be stretched to cover a different product, ingredient, or service.⁴

For another regulatory lens, a 2026 U.S. FDA review proposed not adding MOTS-c free base or acetate to its 503A compounding list.¹² The briefing cited characterization concerns and insufficient human safety and effectiveness information.¹² It remains a U.S. compounding proposal rather than a Philippine ruling.¹²

The same review examined product-quality risks. FDA found that peptide aggregation and impurities could create immune-response concerns, especially for parenteral routes.¹³ That assessment is about compounded MOTS-c-related bulk substances.¹³ It does not describe a specific Philippine product or supply an adverse-event rate.¹³

Read the menu in five passes

First, translate the headline into one measurable outcome: memory, walking, strength, recovery, or another named function. WHO’s healthy-ageing framework centers function and wellbeing rather than one isolated marker.¹ Second, identify the model. Human observation, randomized trial, mouse experiment, and cell study cannot answer the same question.

Third, match the substance and form. The cited NAD-related human trials studied precursors or combinations, not every product called NAD+.² Fourth, read outcomes beside limits. A rise in NAD+ can coexist with no measured cognitive change.⁷ Fifth, verify the establishment and exact health product through the Philippine FDA’s public portal rather than relying on a logo or a scientific-sounding menu.⁴

This approach does not require readers to be cynical. It asks the claim to stay attached to its endpoint, model, comparator, time frame, and regulatory context.

Bottom line

The most persuasive anti-aging language often moves quickly from mechanism to marker, then from marker to a whole-person promise. The evidence moves more slowly. NAD-related human studies show that a metabolic change may occur without a matching gain in cognition, muscle function, or recovery.² MOTS-c research shows another common jump: an intervention result in mice can sit beside a human exercise observation without becoming a human performance result.³ Filipino readers can respond with precise questions, not shame or panic. Name the outcome, check the model, match the exact substance, and use the Philippine FDA Verification Portal for local establishment and product records.⁴

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

What does “anti-aging” mean in a study?

It means little until the researchers name an outcome. WHO frames healthy ageing around functional ability and wellbeing, including mobility, decision-making, relationships, and contribution.¹ A study may instead measure a blood marker or short laboratory response. Readers should keep that narrower measurement attached to the result.

Does raising NAD+ show that ageing slowed?

No single marker can carry that broad conclusion. In one 24-person trial, nicotinamide riboside increased markers of NAD+ metabolism, while most measured cardiovascular and physical-function outcomes did not differ from placebo.^{5 6} The marker and the lived outcome were separate results from the same protocol.

What did the cognitive pilot study find?

The placebo-controlled pilot included 20 older adults with mild cognitive impairment. Nicotinamide riboside raised blood NAD+, but cognition did not change over ten weeks.⁷ The finding belongs to that small population and follow-up; exploratory measurements should not be presented as if they replaced the cognitive endpoint.

Does the MOTS-c exercise paper prove a human performance effect?

No. The intervention improved physical performance in mice, while the human experiment measured the body’s own MOTS-c response around exercise.³ Those are different models and questions. Combining them into a claim that an externally supplied product improves human performance would go beyond what the paper measured.

How can a Filipino reader check a clinic claim?

Ask for the exact establishment name, health product, and claimed outcome. The Philippine FDA says its Verification Portal includes licensed establishments, registered or notified health products, approved clinical trials, and selected product information.⁴ Treat each listing as specific; a record for one item does not cover another.

Is the U.S. MOTS-c review a Philippine decision?

No. The 2026 document is an American compounding review, and FDA proposed excluding two MOTS-c-related substances from a federal bulks list.¹² It also raised aggregation, impurity, and immune-response concerns.¹³ Neither point decides the registration status of a specific health product in the Philippines.

Sources

Footnotes

1. Healthy ageing and functional ability. World Health Organization public-health guidance explaining healthy ageing and functional ability. This is a population-health framework, not a test of any compound or clinic service. ↩ ↩² ↩³ ↩⁴ ↩⁵

2. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults; A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment; NAD+-Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults; A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. Synthesis of four randomized human studies using different precursor formulations, populations, endpoints, and follow-up periods. This is not a pooled effect estimate, and the studies should not be treated as interchangeable or as evidence about direct NAD+ IV products. ↩ ↩² ↩³ ↩⁴

3. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Combined cell, mouse, and small human exercise experiments published in Nature Communications. The mouse intervention result and the human observational exercise signal are different findings and cannot be merged into a human performance claim. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

4. FDA Advisory No. 2023-2238: Utilization of the Food and Drug Administration Verification Portal. Philippine FDA advisory describing the scope and purpose of its public verification portal. The portal is a verification resource, not individualized regulatory advice, and one listing should not be generalized to another product or service. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

5. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Double-blind, placebo-controlled crossover trial in healthy adults aged 55 to 79 years. A change in NAD+ metabolism is a biomarker result and does not by itself establish slower ageing or a broad functional benefit. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

6. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Secondary physiological outcomes from the six-week randomized crossover trial. The trial was small and short, so the result should remain tied to its participants, endpoints, and follow-up. ↩ ↩²

7. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. Placebo-controlled pilot trial in older adults with mild cognitive impairment. The cognitive result is specific to a small pilot population and short follow-up; exploratory measures do not replace the prespecified outcome. ↩ ↩² ↩³ ↩⁴ ↩⁵

8. NAD+-Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults. Double-blind controlled crossover trial with 32-day study periods in community-dwelling older adults with impaired physical function. The tested mixture was not direct NAD+ and the small study does not answer every formulation, population, or endpoint. ↩ ↩² ↩³

9. A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. Placebo-controlled human study using a standardized muscle-injury model in adults aged 55 to 80 years. The finding belongs to the tested combination, injury model, and outcomes; it is not a universal result for all NAD-related compounds. ↩ ↩² ↩³

10. FDA reminds compounders to use ingredients suitable for sterile compounding. FDA safety communication focused on ingredient suitability for sterile preparations. The warning concerns sterile-product quality and should not be generalized to every route, supplier, or finished product. ↩

11. FDA reminds compounders to use ingredients suitable for sterile compounding. FDA safety communication concerning sterile compounding and adverse-event reports. Spontaneous reports do not establish incidence, and this U.S. communication does not determine the status or quality of a specific Philippine product. ↩ ↩²

12. FDA briefing document for MOTS-c-related bulk drug substances. FDA briefing document prepared for the July 2026 Pharmacy Compounding Advisory Committee meeting. This is a U.S. regulatory proposal in a compounding review, not a Philippine ruling or a conclusion about future research. ↩ ↩² ↩³ ↩⁴

13. FDA briefing document for MOTS-c-related bulk drug substances. FDA physicochemical and safety assessment in the 2026 MOTS-c compounding briefing document. This risk assessment concerns compounded MOTS-c-related bulk substances and is not a Philippine product ruling or an adverse-event rate. ↩ ↩² ↩³ ↩⁴